| UniProt ID | FOXC2_HUMAN | |
|---|---|---|
| UniProt AC | Q99958 | |
| Protein Name | Forkhead box protein C2 | |
| Gene Name | FOXC2 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 501 | |
| Subcellular Localization | Nucleus . | |
| Protein Description | Transcriptional activator. Might be involved in the formation of special mesenchymal tissues.. | |
| Protein Sequence | MQARYSVSDPNALGVVPYLSEQNYYRAAGSYGGMASPMGVYSGHPEQYSAGMGRSYAPYHHHQPAAPKDLVKPPYSYIALITMAIQNAPEKKITLNGIYQFIMDRFPFYRENKQGWQNSIRHNLSLNECFVKVPRDDKKPGKGSYWTLDPDSYNMFENGSFLRRRRRFKKKDVSKEKEERAHLKEPPPAASKGAPATPHLADAPKEAEKKVVIKSEAASPALPVITKVETLSPESALQGSPRSAASTPAGSPDGSLPEHHAAAPNGLPGFSVENIMTLRTSPPGGELSPGAGRAGLVVPPLALPYAAAPPAAYGQPCAQGLEAGAAGGYQCSMRAMSLYTGAERPAHMCVPPALDEALSDHPSGPTSPLSALNLAAGQEGALAATGHHHQHHGHHHPQAPPPPPAPQPQPTPQPGAAAAQAASWYLNHSGDLNHLPGHTFAAQQQTFPNVREMFNSHRLGIENSTLGESQVSGNASCQLPYRSTPPLYRHAAPYSYDCTKY | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 36 | Phosphorylation | GSYGGMASPMGVYSG CCCCCCCCCCCCCCC | 13.41 | 22199227 | |
| 77 | Phosphorylation | LVKPPYSYIALITMA HCCCCCHHHHHHHHH | 5.60 | - | |
| 119 | Phosphorylation | NKQGWQNSIRHNLSL CCCCHHHHHHHCCCC | 13.10 | 27251275 | |
| 132 | Sumoylation | SLNECFVKVPRDDKK CCCCEEEECCCCCCC | 26.69 | - | |
| 132 | Sumoylation | SLNECFVKVPRDDKK CCCCEEEECCCCCCC | 26.69 | - | |
| 153 | Phosphorylation | WTLDPDSYNMFENGS EEECHHHCCCCCCCH | 20.30 | - | |
| 184 | Sumoylation | KEERAHLKEPPPAAS HHHHHCCCCCCCHHH | 59.30 | 28112733 | |
| 192 | Acetylation | EPPPAASKGAPATPH CCCCHHHCCCCCCCC | 55.13 | 26051181 | |
| 197 | Phosphorylation | ASKGAPATPHLADAP HHCCCCCCCCCCCCC | 15.35 | 28387310 | |
| 214 | Acetylation | AEKKVVIKSEAASPA HHCCEEEECCCCCCC | 30.54 | 26051181 | |
| 214 | Sumoylation | AEKKVVIKSEAASPA HHCCEEEECCCCCCC | 30.54 | 28112733 | |
| 214 | Sumoylation | AEKKVVIKSEAASPA HHCCEEEECCCCCCC | 30.54 | - | |
| 215 | Phosphorylation | EKKVVIKSEAASPAL HCCEEEECCCCCCCC | 22.73 | 22167270 | |
| 219 | Phosphorylation | VIKSEAASPALPVIT EEECCCCCCCCCEEE | 20.11 | 22167270 | |
| 226 | Phosphorylation | SPALPVITKVETLSP CCCCCEEEEEEECCH | 29.31 | 23927012 | |
| 227 | Acetylation | PALPVITKVETLSPE CCCCEEEEEEECCHH | 27.27 | 26051181 | |
| 230 | Phosphorylation | PVITKVETLSPESAL CEEEEEEECCHHHHH | 35.21 | 25463755 | |
| 232 | Phosphorylation | ITKVETLSPESALQG EEEEEECCHHHHHCC | 33.76 | 25463755 | |
| 235 | Phosphorylation | VETLSPESALQGSPR EEECCHHHHHCCCCC | 37.35 | 23927012 | |
| 240 | Phosphorylation | PESALQGSPRSAAST HHHHHCCCCCCCCCC | 12.27 | 25463755 | |
| 247 | Phosphorylation | SPRSAASTPAGSPDG CCCCCCCCCCCCCCC | 16.66 | 23878394 | |
| 251 | Phosphorylation | AASTPAGSPDGSLPE CCCCCCCCCCCCCCH | 23.17 | 23878394 | |
| 255 | Phosphorylation | PAGSPDGSLPEHHAA CCCCCCCCCCHHHCC | 48.40 | 22817900 | |
| 279 | Methylation | VENIMTLRTSPPGGE EECEEEEEECCCCCC | 24.80 | - | |
| 280 | Phosphorylation | ENIMTLRTSPPGGEL ECEEEEEECCCCCCC | 49.01 | 22167270 | |
| 281 | Phosphorylation | NIMTLRTSPPGGELS CEEEEEECCCCCCCC | 23.74 | 22167270 | |
| 288 | Phosphorylation | SPPGGELSPGAGRAG CCCCCCCCCCCCCCC | 19.58 | 23927012 | |
| 293 | Methylation | ELSPGAGRAGLVVPP CCCCCCCCCCEECCC | 25.58 | - | |
| 367 | Phosphorylation | DHPSGPTSPLSALNL CCCCCCCCCHHHHHH | 27.29 | 23878394 | |
| 458 | Asymmetric dimethylarginine | REMFNSHRLGIENST HHHHHHHCCCCCCCC | 34.14 | - | |
| 458 | Methylation | REMFNSHRLGIENST HHHHHHHCCCCCCCC | 34.14 | - | |
| 472 | Phosphorylation | TLGESQVSGNASCQL CCCCCCCCCCCCCCC | 20.77 | 28348404 | |
| 476 | Phosphorylation | SQVSGNASCQLPYRS CCCCCCCCCCCCCCC | 13.34 | 28348404 | |
| 481 | Phosphorylation | NASCQLPYRSTPPLY CCCCCCCCCCCCCCC | 26.28 | 28348404 | |
| 483 | Phosphorylation | SCQLPYRSTPPLYRH CCCCCCCCCCCCCCC | 39.15 | 28348404 | |
| 484 | Phosphorylation | CQLPYRSTPPLYRHA CCCCCCCCCCCCCCC | 21.67 | 28348404 | |
| 494 | Phosphorylation | LYRHAAPYSYDCTKY CCCCCCCCCCCCCCC | 18.35 | - | |
| 496 | Phosphorylation | RHAAPYSYDCTKY-- CCCCCCCCCCCCC-- | 14.81 | - | |
| 499 | Phosphorylation | APYSYDCTKY----- CCCCCCCCCC----- | 30.40 | - | |
| 501 | Phosphorylation | YSYDCTKY------- CCCCCCCC------- | 12.96 | - |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
| 367 | S | Phosphorylation | Kinase | MAPK14 | Q16539 | GPS |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of FOXC2_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of FOXC2_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| 153400 | Lymphedema-distichiasis (LYD) | |||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-219; SER-232 ANDSER-240, AND MASS SPECTROMETRY. | |
| "A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36; SER-215; SER-219;SER-232; SER-240; SER-281 AND SER-288, AND MASS SPECTROMETRY. | |
| "Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-219, AND MASSSPECTROMETRY. | |
| "Combining protein-based IMAC, peptide-based IMAC, and MudPIT forefficient phosphoproteomic analysis."; Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,Yates J.R. III; J. Proteome Res. 7:1346-1351(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232; SER-235; SER-240AND SER-281, AND MASS SPECTROMETRY. | |
| "Improved titanium dioxide enrichment of phosphopeptides from HeLacells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra."; Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; J. Proteome Res. 6:4150-4162(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-219, AND MASSSPECTROMETRY. | |
| "Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232 AND SER-240, ANDMASS SPECTROMETRY. | |